MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen

PURPOSE: To investigate factors associated with macular atrophy (MA) incidence in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept in an Observe-and-Plan variable dosing regimen. METHODS: Information was obtained from two identical prospective treatment pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantel, Irmela, Dirani, Ali, Zola, Marta, Parvin, Parmis, De Massougnes, Sophie, Bergin, Ciara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2019
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510321/
https://www.ncbi.nlm.nih.gov/pubmed/29370035
http://dx.doi.org/10.1097/IAE.0000000000002054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510321/
https://www.ncbi.nlm.nih.gov/pubmed/29370035
http://dx.doi.org/10.1097/IAE.0000000000002054

Ejemplares similares